<< Предыдущая

стр. 8
(из 9 стр.)

ОГЛАВЛЕНИЕ

Следующая >>

взрослых. with perinatal HIV-1 infection. J. Am. Med. Assoc. 284 (2000),
190–7.
При выборе схемы АРТ для конкретного ребенка
7. Hammer, S. M., Squires, K. E., Hughes, M.D. et al. Controlled
следует учитывать множество факторов, включая проти-
trial of two nucleoside analogues plus indinavir in persons with
вовирусную активность и токсичность различных ком-
human immunodeficiency virus infection and CD4 cell counts of
бинаций препаратов, сложность режима приема препара-
200 per cubic millimeter or less. AIDS Clinical Trials Group
тов, лекарственные взаимодействия с другими препара- 320 Study Team. New Engl. J.Med. 337 (1997), 725–33.
тами, которые принимает ребенок, способность ребенка
8. Fischl, M. A., Richman, D.D.,Grieco, M. H. et al. The efficacy
и членов его семьи соблюдать режим приема препаратов,
of azidothymidine (AZT) in the treatment of patients with AIDS
а также прием антиретровирусных препаратов в про- &AIDS-related complex. New Engl. J.Med. 317 (1987), 185–91.
шлом. Согласно действующим американским рекомен-
9. Idemyor, V. Commentary: Continuing debate over HIV therapy
дациям, показаниями к началу антиретровирусной тера- initiation. HIV Clin. Trials 3 (2002), 173–6.
пии у ребенка первого года жизни служат любые клини-
10. Volberding, P. A., Lagakos, S.W., Koch, M. A. et al.
ческие симптомы ВИЧ-инфекции или признаки иммуно-
Zidovudine in asymptomatic human immunodeficiency virus
дефицита, даже легкого, в то время как ребенку старше infection – a controlled trial in persons with fewer than 500
года при отсутствии симптомов ВИЧ-инфекции или CD4- positive cells per cubic millimeter. New Engl. J.
наличии симптомов легкой тяжести и легком Med.322(1990), 941–9.
иммунодефиците терапию не назначают. Схема выбора 11. Concorde Coordinating Committee. Concorde: MRC/ANRS
включает сильнодействующий ИП или препарат класса randomized, double-blind controlled trial of immediate and
ННИОТ ифавиренц в комбинации с двумя НИОТ. В deferred zidovudine in symptom-free HIV infection. Lancet 343
Европе показания к проведению АРТ у детей старшего (1994), 871–81.
возраста аналогичны американским; рекомендации же 12. Pediatric European Network for Treatment of AIDS (PENTA).
для детей первого года жизни более консервативны, Five year follow-up of vertically HIV infected children in a
поскольку таким детям не рекомендуется начинать randomised double blind controlled trial of immediate verus
deferred zidovudine: the PENTA 1 trial. Arch. Dis. Child. 84
терапию до выраженного ухудшения вирусологических,
(2001), 230–6.
иммунологических и клинических показателей. Чтобы
13. Mannheimer, S., Friedland, G., Matts, J. et al. The consistency
снизить риск формирования резистентности, при
of adherence to antiretroviral therapy predicts biologic outcomes
появлении клинических, иммунологических или
for human immunodeficiency virus-infected persons in clinical
вирусологических признаков неэффективности терапии
trials. Clin. Infect. Dis. 34 (2002), 1115–21.
схему АРТ следует заменить, при этом новая схема АРТ




Руководство по оказанию помощи ВИЧ-инфицированным детям. Под ред. С. Зайхнера и Дж. Рид
22-24 Линн Мофенсон, Лесли Серчук



14. Paterson, D., Swindells, S., Mohr, J. et al. Adherence to protease absence of persistent HIV-1 specific immune responses. J. Virol.
inhibitor therapy and outcomes in patients with HIV infection. 74 (2000), 6984–91.
Ann. Intern. Med. 133 (2000), 21–30. 32. Luzuriaga, K.,McManus, M., Mofenson, L. et al. A trial of three
15. Bartlett, J. A. Addressing the challenges of adherence. J. Acquir. antiretroviral regimens in HIV-1-infected children. N. Engl. J.
Immune Defic. Syndr. 29 (2002), S2-S10. Med. 350 (2004), 2471–80.
16. Van Dyke, R. B., Lee, S., Johnson, G. M. et al. Reported 33. Hainault, M., Peltier, C. A., Gerard, M. et al. Effectiveness of
adherence as a determinant of response to highly active antiretroviral therapy initiated before the age of 2 months in
antiretroviral therapy in children who have human infants vertically infected with human immunodeficiency virus
immunodeficiency virus infection. Pediatrics 109: 4 (2002), type 1. Eur. J. Pediatr. 159 (2000), 778–82.
URL: http://www.pediatrics.org/cgi/content/full/109/e61. 34. Faye, A., Bertone, C., Teglas, J. P. et al. Early multitherapy
17. Pontali, E., Feasi, M., Toscanini, F. et al. Adherence to including a protease inhibitor for human immunodeficiency
combination antiretroviral treatment in children. HIV Clin. virus type 1-infected infants. Pediatr. Infect. Dis. J. 21 (2002),
Trials 2 (2001), 466–73. 518–25.
18. McKinney, R. E., Johnson, G. M., Stanley, K. et al. A 35. Altfeld, M., Rosenberg, E. S., Shankarappa, R. et al. Cellular
randomized study of combined zidovudine-lamivudine versus immune responses and viral diversity in individuals treated
didanosine monotherapy in children with symptomatic therapy- during acute and early HIV-1 infection. J.Exp. Med. 193 (2001),
naive HIV-1 infection. J. Pediatr. 133 (1998), 500–8. 169–80.
19. Englund, J., Baker, C., Raskino, C. et al. Zidovudine, didanosine 36. Markowitz, M., Vesanen, M., Tenner-Racz, K. et al. The effect
or both as initial treatment for symptomatic HIV-infected of commencing combination antiretroviral therapy soon after
children. New Engl. J. Med. 336 (1997), 1704–12. human immunodeficiency virus type 1 infection on viral
replication and antiviral immune responses. J. Infect. Dis. 179
20. Fischl, M. A., Richman, D.D., Hansen, N. et al. The safety and
(1999), 525–37.
efficacy of zidovudine in the treatment of subjects with mildly
symptomatic HIV infection: a double-blind, placebo controlled 37. Carr, A. & Cooper, D. A. Adverse effects of antiretroviral
trial. Ann. Intern. Med. 112 (1990), 727–37. therapy. Lancet 356 (2000), 1423–30.
21. Volberding, P. A, Lagakos, S.W., Grimes, J. M. et al. The 38. Melvin, A. J., Lennon, S., Mohan, K. M. & Purnell, J. Q.
duration of zidovudine benefit in persons with asymptomatic Metabolic abnormalities in HIV type 1-infected children treated
HIV infection – prolonged evaluation of protocol 019 of the and not treated with protease inhibitors. AIDS Res. Hum.
AIDS Clinical Trials Group. J. Am. Med. Assoc. 272 (1994), Retrovirus. 17 (2001), 1117–23.
437–42. 39. Arpadi, S. M., Cuff, P. A., Horlick, M., Wang, J. & Kotler, D. P.
22. Pizzo, P. A., Eddy, J., Falloon, J. et al. Effect of continuous Lipodystrophy in HIV-infected children is associated with high
intravenous infusion of zidovudine (AZT) in children with viral load and low CD4+-lymphocyte count and CD4+-
symptomatic HIV infection. New Engl. J. Med. 319 (1988), lymphocyte percentage at baseline and use of protease inhibitors
889–96. and stavudine. J. AIDS Hum. Retrovirol. 27 (2001), 30–4.
23. McKinney, R. E., Maha, M. A., Connor, E.M. et al. A 40. Mora, S., Sala, N., Bricalli, D., Zuin, G., Chiumello, G., &
multicenter trial of oral zidovudine in children with advanced Vigano, A. Bone mineral loss through increased bone turnover
human immunodeficiency virus disease. New Engl. J. Med. 324 in HIV infected children treated with highly active antiretroviral
(1991), 1018–25. therapy. AIDS 15 (2001), 1823–9.
24. Butler, K. M., Husson, R. N., Balis, F. M. et al. Dideoxyinosine 41. Cossarizza, A., Pinti, M., Moretti, L. et al. Mitochondrial
in children with symptomatic human immunodeficiency virus functionality and mitochondrial DNA content in lymphocytes of
infection. New Engl. J. Med. 324 (1991), 137–44. vertically infected human immunodeficiency virus positive
children with highly active antiretroviral therapy related
25. Lewis, L. L., Venzon, D., Church, J. et al. Lamivudine in
lipodystrophy. J. Infect. Dis. 185 (2002), 299–305.
children with human immunodeficiency virus infection: a phase
I/II study. J. Infect. Dis. 174 (1996), 16–25. 42. Brambilla, P., Bricalli, D., Sala, N. et al. Highly active
antiretroviral-treated HIV-infected children show fat distribution
26. Kline, M.W., Dunkle, L. M., Church, J. A. et al. A phase I/II
changes even in absence of lipodystrophy. AIDS 15 (2001),
evaluation of stavudine (d4T) in children with human
2415–22.
immunodeficiency virus infection. Pediatrics 96 (1995), 247–
52. 43. Galli, L., deMartino, M., Tovo, P. A. et al. Predictive value of
the HIV paediatric classification system for the long-term course
27. Gray, L., Newell, M. L., Thorne, C. et al. Fluctuations in
of perinatally infected children. Int. J. Epidemiol. 29 (2000),
symptoms in human immunodeficiency virus-infected children:
573–8.
the first 10 years of life. Pediatrics, 108 (2001), 116–22.
44. Mofenson, L. M., Korelitz, J., Meyer, W. A. et al. The
28. HIV Paediatric Prognostic Markers Collaborative Study Group.
relationship between serum human immunodeficiency virus type
Short-term risk of disease progression in HIV-1-infected
1 (HIV- 1) RNA level, CD4 lymphocyte percent, and long-term
children receiving no antiretroviral therapy or zidovudine
mortality risk in HIV-1-infected children. J. Infect. Dis. 175
monotherapy: estimates according to CD4 percent, viral load,
(1997), 1029–38.
and age. Lancet 362 (2003), 1605–11.
45. Palumbo, P. E., Raskino, C., Fiscus, S. et al. Virologic and
29. Abrams, E. J., Wiener, J., Carter, R. et al. Maternal health
immunologic response to nucleoside reverse-transcriptase
factors and early pediatric antiretroviral therapy influence the
inhibitor therapy among human immunodeficiency virus
rate of perinatal HIV-1 disease progression in children. AIDS 17
infected infants and children. J. Infect. Dis. 179 (1999), 576–83.
(2003), 867–77.
46. Palumbo, P. E., Raskino, C., Fiscus, S. et al. Predictive value of
30. Luzuriaga, K., Bryson, Y., Krogstad, P. et al. Combination
quantitative plasma HIV RNA and CD4+ lymphocyte count in
treatment with zidovudine, didanosine and nevirapine in infants
HIV-infected infants and children. J. Am. Med. Assoc. 279
with human immunodeficiency virus type 1 infection. New Engl.
(1998), 756–61. 47. Sharland, M., Gibb, D. & Giaquinto, C. on
J.Med. 336 (1997), 1343–9.
behalf of the PENTA Steering Committee. Current evidence for
31. Luzuriaga, K., McManus, M., Catalina, M. et al. Early therapy
of vertical HIV-1 Infection: Control of viral replication and




Руководство по оказанию помощи ВИЧ-инфицированным детям. Под ред. С. Зайхнера и Дж. Рид
22-25
АРТ: начало лечения и замена схемы лечения



the use of paediatric antiretroviral therapy – a PENTA analysis. nevirapine, nelfinavir, or ritonavir in stable, antiretroviral
Eur. J. Pediatr. 159 (2000), 649–56. experienced HIV-infected children: week 24 results of a
randomized controlled trial – PACTG 377. AIDS Res. Hum.
48. Delta Coordinating Committee. Delta: a randomized, double
Retrovirus. 16 (2000), 1113–21.
blind controlled trial comparing combinations of zidovudine
plus didanosine or zalcitabine with zidovudine alone in HIV 65. Floren, L. C., Wiznia, A., Hayashi, S. et al. Nelfinavir
infected individuals. Lancet 348 (1996), 283–91. pharmacokinetics in stable human immunodeficiency virus-
positive children: Pediatric AIDS Clinical Trials Group protocol
49. Hammer, S. M., Katzenstein, D. A., Hughes, M.D. et al. A trial
377. Pediatrics 112 (2003), e220–227. URL:
comparing nucleoside monotherapy with combination therapy in
http://www.pediatrics.org/cgi/content/full/112/3/e220.
HIV- infected adults with CD4 cell counts from 200 to 500 per
cubic millimeter. New Engl. J. Med. 335 (1996), 1081–90. 66. Van Rossum, A. M. C., Geelen, S. P. M., Hartwig, N. G., et al.
Results of 2 years of treatment with protease inhibitor containing
50. Hammer, S. M., Squires, K. E., Hughes, M.D. et al. A controlled
antiretroviral therapy in Dutch children infected with human
trial of two nucleoside analogues plus indinavir in persons with
immunodeficiency virus type 1. Clin. Infect. Dis. 34 (2002),
human immunodeficiency virus infection and CD4 counts of
1008–16.
200 per cubic millimeter or less. New Engl. J. Med. 337 (1997),
725–33. 67. Verweel, G., van Rossum, A. M. C., Hartwig, N. et al.
Treatment with highly active antiretroviral therapy in human
51. Collier, A. C., Coombs, R.W., Schoenfeld, D. A. et al.
immunodeficiency virus type 1-infected children is associated
Treatment of human immunodeficiency virus infection with
with a sustained effect on growth. Pediatrics 109: 2 (2002), E25
saquinavir, zidovudine and zalcitabine. New Engl. J. Med.
URL: http://www.pediatrics.org/cgi/content/full/109/2/e25.
334(1996), 1011– 17.
68. Miller, T. L., Mawn, B. E., Orav, E. J. et al. The effect of
52. Nachman, S. A., Stanley, K., Yogev, R. et al. Nucleoside
protease inhibitor therapy on growth and body composition in
analogs plus ritonavir in antiretroviral-experienced HIV-infected
human immunodeficiency virus type 1-infected children.
children – a randomized controlled trial. J. Am. Med. Assoc. 283
Pediatrics 107: 5 (2001), E77. URL: http://www.pediatrics.org/
(2000), 492–8.
cgi/content/full/107/5/e77.
53. Eastman, P. S., Shapiro, D. E., Coombs, R.W. et al. Maternal
69. Jankelevich, S., Mueller, B. U., Mackall, C. L. et al. Long-term
viral genotypic zidovudine resistance and infrequent failure of
virologic and immunologic responses in human
zidovudine therapy to prevent perinatal transmission of human
immunodeficiency virus type 1-infected children treated with
immunodeficiency virus type 1 in pediatric AIDS Clinical Trials
indinavir, zidovudine and lamivudine. J. Infect. Dis. 183 (2001),
Group Protocol 076. J. Infect. Dis. 177: 3 (1998), 557– 64.
1116–20.
54. McSherry, G.D., Shapiro, D. E., Coombs, R.W. et al. The
70. Starr, S. E., Fletcher, C. V., Spector,S. A. et al. Combination
effects of zidovudine in the subset of infants infected with
therapy with efavirenz, nelfinavir, and nucleoside reverse
human immunodeficiency virus type-1 (Pediatric AIDS Clinical
transcriptase inhibitors in children infected with human
Trials Group Protocol 076). J. Pediatr., 134: 6 (1999), 717–24.
immunodeficiency virus type 1. New Engl. J. Med. 341 (1999),
55. Parker, M. M., Wade, N., Lloyd, R. M. Jr. et al. Prevalence of 1874–81.
genotypic drug resistance among a cohort of HIV-infected
71. Staszewski, S.,Morales-Ramirez, J., Tashima, K. et al. Efavirnez
newborns. J. AIDS 32: 3 (2003), 292–7.
plus zidovudine and lamivudine, efavirenz plus indinavir, and
56. Paediatric European Network for Treatment of AIDS (PENTA). indinavir plus zidovudine and lamivudine in the treatment of
Comparison of dual nucleoside-analogue reverse transcriptase HIV-1 infection in adults. New Engl. J. Med. 341 (1999), 1865–
inhibitor regimens with and without nelfinavir in children with 73.
HIV-1 who have not previously been treated: the PENTA 5
72. Friedl, A. C., Ledergerber, B., Flepp, M. et al. Response to first
randomised trial. Lancet, 359: 9308 (2002), 733–40.
protease inhibitor- and efavirenz-containing antiretroviral
57. Hetherington, S. Understanding drug hypersensitivity: what to combination therapy – the Swiss HIV Cohort Study. AIDS 15
look for when prescribing abacavir. AIDS Reader 11 (2001), (2001), 1793–800.
620–2. 58. Hewitt, R. G. Abacavir hypersensitivity reaction.
73. Starr, S. E., Fletcher, C. V., Spector, S. A. et al. Efavirenz liquid
Clin. Infect. Dis. 34 (2001), 1137–42.
formulation in human immunodeficiency virus-infected
59. Carr, A. & Cooper, D. A. Adverse effects of antiretroviral children. Pediatr. Infect. Dis. J. 21: 7 (2002) 659–63.
therapy. Lancet 356 (2000), 1423–30.
74. Verweel, G., Sharland, M., Lyall, H. et al. Nevirapine use in
60. Coghlan, M. E., Sommadossi, J.-P., Jhala, N. C. et al. HIV-1-infected children. AIDS 17 (2003), 1639–47.
Symptomatic lactic acidosis in hospitalized antiretroviral-treated
75. Saez-Llorens, X., Nelson, R. P., Emmanuel, P. et al. A
patients with human immunodeficiency virus infection: a report
randomized, double-blind study of triple nucleoside therapy of
of 12 cases. Clin. Infect. Dis. 33 (2001), 1914–21.
abacavir, lamivudine, and zidovudine versus lamivudine and
61. Saez-Llorens, X.,Violari, A.,Deetz, C.O. et al. Forty-eight-week zidovudine in previously treated human immunodeficiency virus
evaluation of lopinavir/ritonavir, a new protease inhibitor, in type 1-infected children. Pediatrics 107 (2001), e4. URL:
human immunodeficiency virus-infected children. Pediatr. http://www.pediatric.org/cgi/content/full/107/1/e4.
Infect. Dis. J. 22: 3 (2003), 216–24.
76. Van Rossum, A. M., Dieleman, J. P., Fraaij, P. L. et al.
62. Saez-Llorens, X., Violari, A., Deetz, C.O. et al. Forty-eight- Persistent sterile leukocyturia is associated with impaired renal
week evaluation of lopinavir/ritonavir, a new protease inhibitor, function in human immunodeficiency virus type 1-infected
in human immunodeficiency virus-infected children. Pediatr. children treated with indinavir. Pediatrics 110: 2 (2002), e19.
Infect. Dis. J. 22(3) (2003), 216–24.
77. Cozzi-Lepri, A., Phillips, A. N., d’Arminio Monforte, A. et al.
63. Krogstad, P., Lee, S., Johnson, G. et al. Nucleoside-analogue Virologic and immunologic response to regimens containing
reverse transcriptase inhibitors plus nevirapine, nelfinavir, or nevirapine or efavirenz in combination with 2 nucleoside
ritonavir for pretreated children infected with human analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.)
immunodeficiency virus type 1. Clin. Infect. Dis. 34 (2002), study. J. Infect. Dis. 185: 8 (2002), 1062–9.
991–1001.
78. Nunez, M., Soriano,V., Martin-Carbonero, L. et al. SENC
64. Wiznia, A., Stanley, K., Krogstad, P. et al. Combination (Spanish efavirenz vs. nevirapine comparison) trial: a
nucleoside-analogue reverse transcriptase inhibitor(s) plus




Руководство по оказанию помощи ВИЧ-инфицированным детям. Под ред. С. Зайхнера и Дж. Рид
22-26 Линн Мофенсон, Лесли Серчук



randomized, open-label study in HIV-infected naive individuals. T-20 in human immunodeficiency virus 1-infected children.
HIV Clin. Trials 3(3) (2002), 186–94. Pediatr. Infect. Dis. J. 21 (2002), 653–9.
79. van Leth, F., Phanuphak, P., Ruxrungtham, K. et al. Comparison 89. van Rossum, A. M. C., de Groot, R., Hartwig, N. G. et al.

<< Предыдущая

стр. 8
(из 9 стр.)

ОГЛАВЛЕНИЕ

Следующая >>